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INTRODUCTION
Rheumatoid arthritis (RA) is a systemic inflammatory dis-
ease, characterised by chronic synovitis and progressive
joint destruction. The etiology of RA is multifactorial and
includes a significant genetic component. Cytokines act as
mediators of immune and inflammatory responses and play
an important role in the pathophysiology of joint inflamma-
tion and destruction (Feldmann et al., 1996). A central fea-
ture of RA is a relative imbalance of cytokine production
with a relative excess of proinflammatory molecules, com-
pared with antiinflammatory mediators (Feldmann et al.,
1996). It has been observed that the production of proin-
flammatory cytokines is markedly increased in serum and
synovial fluid in RA patients. The expression levels of cyto-
kines have a genetic background. Single nucleotide poly-
morphisms (SNPs), the most common genetic variations
that have been identified in the cytokine genes promoter,
may be responsible for variations in cytokine production.
The successful therapeutic use of inhibitors of proinflamma-
tory cytokines (TNF-, IL-6) underlines the importance of
these molecules in driving rheumatoid inflammation and
tissue damage. However, non-responder or partial responder
patients are not uncommon, and inflammatory disease can
flare on discontinuation of treatment. Therefore, new thera-
peutic targets in RA should be investigated.
Interleukin 18 (IL-18), a member of the IL-1 superfamily,
was first identified as an interferon- (IFN-) inducing fac-
tor (Okamura et al., 1995). It is widely expressed in human
tissues (Dinarello et al., 1998). IL-18 in RA is produced
predominantly by tissue macrophages (Gracie et al., 1999;
Tanaka et al., 2001; Yamamura et al., 2001). In addition,
mature IL-18 may also be released from dendritic cells
(Gardella et al., 1999), neutrophils (Westphal et al., 2006)
and endothelial cells (Yamaoka-Tojo et al., 2003).
IL-18 has a highly diverse range of biological function.
IL-18 induces the synthesis of TNF-, granulocyte-macro-
phage colony stimulating factor, nitric oxide, and chemo-
kines by T cells and natural killer cells (Dinarello, 1999).
IL-18 directly activates synovial macrophages, promotes
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Interleukin 18 (IL-18) is a proinflammatory cytokine involved in the pathogenesis of rheumatoid ar-
thritis (RA). There are controversial reports suggesting that IL-18 promoter polymorphisms may
be an independent marker of RA susceptibility. The aim of the present study was to determine
whether polymorphisms of the IL-18 gene promoter in positions -607 (rs 1946519) and -656
(rs 1946518) are associated with RA, and its characteristics in the Latvian population. We exam-
ined 105 patients with RA diagnosed according to the criteria of the American College of
Rheumatology. DNA and phenotypic data from a healthy control population was obtained from
Genome Database of Latvian Population. Genotypes were obtained by direct sequencing. Sin-
gle-nucleotide polymorphisms (SNPs) were studied and frequencies of alleles and genotypes
were compared between patients and controls. A P value less than 0.05 was accepted as statisti-
cally significant. There were no significant differences in the distribution of alleles and genotypes
between RA patients and the control group. The frequencies of IL-18-607C/A and -656G/T geno-
types differed between patients and the control group in women (P = 0.084 and 0.097). Heterozy-
gous genotypes -607CA and -656GT occurred more frequently in the RA group than in the control
(P = 0.046, P = 0.060), and this difference was also significant for the only women groups (P =
0.041, P = 0.054). The heterozygous states -607CA and -656GT of IL-18 gene affect susceptibil-
ity to RA. On the basis of investigated IL-18 polymorphisms, female patients with RA seem to rep-
resent a separate disease subgroup.
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production of proinflammatory cytokines such as TNF-
and IL-1 (Gracie et al., 1999), induces the production of
hemokines and expression of adhesion molecules by
synovial fibroblasts (Morel et al., 2001; 2002), and stimu-
lates angiogenesis (Park et al., 2001). IL18 indirectly stimu-
lates osteoklastogenesis through upregulation of membrane
bound receptor activator of NFkB ligand (RANKL) produc-
tion from RA synovial T cells or through induction of
TNF-, IL-1 and IL-6 (Dai et al., 2004).
IL-18 has been found in synovial tissue, and enhanced lev-
els of IL-18 were observed in the serum and in the joint of
RA patients (Gracie et al., 1999). Serum and synovial fluid
IL-18 levels as well as synovial tissue IL-18 expression
were correlated with disease activity parameters (erythro-
cyte sedimentation rate (ESR), serum C-reactive protein
(CRP), and Disease Activity Score (DAS 28) ) (Yamamura
et al., 2001; Joosten et al., 2003; Rooney et al., 2004;
Petrovic-Rackov et al., 2006).
The IL-18 gene maps to chromosome 11q22.2-q22.3 (Nolan
et al., 1998). Several single-nucleotide polymorphisms
(SNPs) in the promoter region in the IL-18 gene are present,
which may affect IL-18 expression. Allelic variants of cyto-
kine genes associated with promoter gene region polymor-
phisms do not influence the protein amino acid sequence
but can result in changes of cytokine production. The -607
C/A SNP is located at the binding sites for CREB transcrip-
tional factors (cAMP response-element binding proteins),
and therefore, mutations at this site can influence IL-18 ex-
pression and change the production of the cytokine (Gie-
draitis et al., 2001).
The aim of the present study was to examine two IL-18
gene SNPs in positions -607 (rs 1946519) and -656 (rs
1946518) in the promoter region in relation to the RA sus-
ceptibility, activity and severity.
MATERIALS AND METHODS
Patient population. A total of 105 patients with established
RA (women and men) according to the well-known revised
criteria of the American College of Rheumatology (ACR)
for RA (Arnett et al., 1988) were consecutively recruited
into the study during a one-year period. Patients with RA
were recruited from the outpatient and inpatient populations
in the Rheumatology Department Clinic “Linezers”, Rîga
Eastern Hospital, Latvia. Informed consent was obtained
from all patients.
Evaluation of the patients included a physical examination
with a particular focus on the pattern of joint involvement
and laboratory analyses. The following data were obtained
from the RA patients: age of disease onset, number of ten-
der (TEN) and swollen (SW) joints, visual analogue scale
(VAS) of pain and disease activity, physician assessment of
disease activity, presence and value of rheumatoid factor
(RF) and anti-cyclic-citrullinated peptides (antiCCP) anti-
bodies, C-reactive protein (CRP), erythrocyte sedimentation
rate (ESR), and rentgenological (RTG) stage. The modified
disease activity score DAS28 was calculated as described
(Prevoo et al., 1995). Simple x-rays of the hands and feet
were analysed using the Steinbrocker method (Pincus et al.,
1997). Within the RA group, eight patients lacked evidence
of joint erosions on the radiograph (stage I: nonerosive RA)
and 97 patients had erosions (stages II–IV: erosive RA; 19 –
stage II, 75 – stage III, and 3 – stage IV). Demographic,
clinical, and laboratory characteristics of RA patients are
summarised in Table 1.
A total of 242 healthy subjects with similar age and sex dis-
tribution were available for the study from Genome Data-
base of Latvian Population (median 53, range 17–84 years,
female 195 (81.3%), male 45 (18.8%)).
Genetic analysis. Genotypes were obtained by direct se-
quencing. Analysis of SNPs at the -607 and -656 positions
of the IL-18 gene were studied.
Genomic DNA was extracted from peripheral blood sam-
ples using the standard phenol-chloroform extraction
method. The IL18 promoter region harbouring SNPs at po-
sitions -607 and -656 was PCR amplified using forward 5’-
ATTCAGGACTTCCCCTTCCT-3’ and reverse 5’-
CACTCTGCTCTTCAAACGTTACAT -3’ primers. Ampli-
cons were then purified using Sap-ExoI protocol and the se-
quences were obtained by direct sequencing of amplified
products using forward PCR primer on a 3100 ABI prism
DNA sequencer (Applied Biosystems).
T a b l e 1
DEMOGRAPHIC, CLINICAL AND LABORATORY CHARACTERIS-
TICS OF PATIENTS WITH RHEUMATOID ARTHRITIS
Characteristics RA patients,
n =105
Age (years) 58 (26–83)
Female sex (%) 89 (84.8)
Male sex (%) 16 (15.2)
RA onset
before 50 y.o. 47 (44.8)
after 50 y.o. 58 (55.2)
Disease duration (years) 4.7 (0.1–49.4)
Swollen joint count (28) 6 (0–20)
Tender joint count (28) 8 (0–26)
VAS pain (mm) 49 (1–97)
VAS disease activity (mm) 50 (2–93)
VAS physician’s assessment (mm) 34 (4–89)
ESR (mm/h) 26 (2–76)
CRP (mg/l) 6.90 (0.00–113.4)
DAS28 (ESR) 5.04 (0.93–7.77)
DAS28 (CRP) 4.5 (1.84–7.6)
Rheumatoid factor positivity 79 (76.7)
Rheumatoid factor negativity 24 (23.3)
AntiCCP positivity 58 (79.6)
AntiCCP negativity 15 (20.6)
Values are given as medians (range) or as number (%)
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The following PCR mix and conditions were used. PCR
mix per sample contained 15 mkl of 2x PCR Master Mix
(Fermentas Life Sciences, Lithuania), forward and reverse
primers (1 mM) and 28 ng of dried genomic DNA. The cy-
cling conditions for PCR were: 5 minutes of initial denatu-
ration at 95 °C, followed by 32 cycles of 15 seconds at
95 °C, 30 seconds at 56 °C, 30 seconds at 72 °C, and final
extension for 10 minutes at 72 °C.
Statistical analysis. The chi-squared test was used for the
calculation of the deviation from the Hardy-Weinberg equi-
librium. Fisher’s exact test and chi-square tests was used to
examine allele/genotype association with presence of RA
and other qualitative variables (positive RF, anti CCP and
others). Dichotomised variables were created for RF and
anti- CCP levels (for RF positivity 14 IU/ml; for antiCCP
positivity > 5.0 units/ml). ANOVA tests was used to com-
pare quantitative variables (age at onset of RA, VAS,
DAS28, SW28, TEN28, CRP, ESR) between geno-
type-stratified subgroups of RA patients. A P value less
than 0.05 was considered statistically significant. Odds ra-
tios (OR) were calculated with a 95% confidence interval
(CI). All statistics were conducted using the software pack-
age SPSS, version 13.0.
RESULTS
All genotyping results fit Hardy-Weinberg equilibrium. The
distribution of alleles and genotypes is shown in Table 2.
There were no significant differences in the distribution of
the IL-18 gene alleles and genotypes between RA patients
and the control group, but we found a difference in the fre-
quencies of IL-18-607C/A and -656G/T genotypes, not al-
leles, between RA patients and the control group in women
(Table 3).
We found a significant difference between frequencies of
heterozygous versus homozygous genotypes; heterozygous
genotypes -607CA and -656GT occurred more frequently in
the RA group than in the control (Table 4). This difference
was even larger when only women were considered (Table
5).
There were no differences in marker distributions between
RA patients and the control for different age groups, men
and control groups (data not shown). There were no differ-
ences found between age of onset RA, disease activity pa-
rameters (ESR, CRP, DAS28, SW28, TEN28), antibody
status (RF positive/negative; antiCCP positive/negative),
and RTG stages in RA group (data not shown).
DISCUSSION
In the present study we examined SNPs at the -607 and -656
positions of the IL-18 gene in the patients with RA, in rela-
tion to disease susceptibility, activity and severity.
We found a significant difference in between RA patients
and the control group in the distribution of heterozygous
versus homozygous genotypes. A significant difference was
also found when only the respective women groups were
examined. Reports evaluating the role of IL-18 promoter
T a b l e 2
ALLELIC AND GENOTYPIC FREQUENCIES OF IL-18 GENE
POLYMORPHISMS IN LATVIAN PATIENTS WITH RA AND CON-
TROLS
RA, n (%) Controls, n (%) P-value
IL-18-656G/T

























Values are given as number (%)
Odds ratio and the confidence interval at the 95% confidence level is indi-
cated as OR and 95%CI, respectively
*OR, 95%CI 0.986, 0.78–1.25
**OR, 95%CI 1.02, 0.81–1.29
T a b l e 3
ALLELIC AND GENOTYPIC FREQUENCIES OF IL-18 GENE
POLYMORPHISMS IN LATVIAN WOMEN WITH RA AND CON-
TROLS
RA, n (%) Controls, n (%) P-value
IL-18-656G/T

























Values are given as number (%)
Odds ratio and the confidence interval at the 95% confidence level is indi-
cated as OR and 95%CI, respectively
*OR, 95%CI 1.00, 0.74–1.28
**OR, 95%CI 1.01, 0.79–1.30
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polymorphisms in RA patients have shown variable results
for different SNPs. Sivalingam et al (2003) found that con-
trols had significantly higher frequency of the AA genotype
at position -607 when compared to RA patients and con-
cluded that the AA genotype at position -607 is associated
with a protective effect against development of RA in Chi-
nese individuals. Rueda et al. (2005) observed no statisti-
cally significant differences between RA patients and con-
trols in allelic and genotypic frequencies of -607C/A and
-137C/G IL-18 promoter polymorphisms. In addition, no
association was found with the haplotypes inferred by the
two polymorphisms and RA susceptibility. RA patients
were stratified according to sex, age at the onset of the dis-
ease rheumatoid factor status, and extraarticular manifesta-
tions and no association was found with these poly-
morphisms. Therefore, the conclusion is that studied
polymorphisms within the IL-18 promoter region do not
play a major role in RA predisposition.
Gracie et al. (2005) found that the -607C/-137C haplotype
was more prevalent in Caucasian RA patients than in a con-
trol group and concluded that SNP of both positions con-
tribute to the genetic background of RA pathogenesis.
Lee et al. (2007) reported a significantly higher frequency
of the 105A allele of the IL-18-105A/C SNP in Chinese
rheumatoid arthritis patients compared with controls. The
relative risk of rheumatoid arthritis was stronger in 105A
homozygotes. Sugiura et al. (2006) showed that 12 SNP
within the promoter region of the IL-18 gene were associ-
ated with susceptibility to juvenile idiopathic arthritis (JIA)
in Japanese patients. There was a strong association be-
tween the diplotype configuration of S01/S01 of the IL-18
gene and JIA. T at position -656, A at position -607, and G
at position -137 were the components of haplotype S01.
In the recent study by Pawlik et al. (2009), where seven IL-
18 gene SNPs were studied, no significant differences were
found in the distributions of the genotypes except for
rs360722 and haplotypes between RA patients and a control
group. Age at RA diagnosis was lower in carriers of the
-607 CC and rs187238 GG genotypes. Erosive disease was
diagnosed more frequently in patients with the -607 CC and
AC genotypes than in AA homozygotes.
A possible explanation for the discordant results could be
linkage with other polymorphisms within the gene or within
other genes; another one might be the variation of genetic
susceptibility between ethnic groups (Burchard et al.,
2003). Allelic heterogeneity exists between ethnic groups,
and different variations within the same gene can contribute
to disease risk (Colhoun et al., 2003).
It is well known that gene promoter polymorphisms can af-
fect the level of protein production. The gene sequence can
be associated with a cytokine phenotype. Homozygotes for
the high-producer allele are the highest producers of the
cytokine, homozygotes for the low-producer allele are the
lowest producers of the cytokine and heterozygotes are in-
termediate. On the other hand, we can assume that homozy-
gotes for the allele are the lowest producers of the cytokine
and heterozygotes are the highest producers of the cytokine.
Khripko et al. (2008) studied distribution of IL-18 allele
variants at positions -607C/A and -137G/C in healthy do-
nors from Siberia and the influence of these allele variants
on the level of IL-18 production by peripheral blood
mononuclear cells (PBMCs). The authors found that
lipopolysaccharide (LPS)-stimulated production of IL-18 by
PBMC from healthy donors was significantly greater in
T a b l e 4
GENOTYPIC FREQUENCIES OF IL-18 GENE POLYMORPHISMS IN
LATVIAN PATIENTS WITH RA AND CONTROLS
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GENOTYPIC FREQUENCIES OF IL-18 GENE POLYMORPHISMS IN
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those carrying the CA genotype at the -607 position, com-
pared with donors with the -607CC genotype.
RA is one of many autoimmune diseases that is predomi-
nant in women, as it has a female-to-male ratio 2:1 to 3:1.
Sex hormones can have significant effects on the cells
known to participate in RA. However, the specific mecha-
nisms responsible for increased susceptibility to RA in
women are uncertain. Padyukov et al. (2004) showed an as-
sociation of IL10 -1087 genotypes in woman with RA com-
pared with men and controls. The observed difference in
frequencies of alleles and genotypes of the IL-18 gene in
positions -607 and -656 between RA patients and the con-
trol group in women suggests that RA in woman is a differ-
ent disease subset. Further studies are needed and using a
larger patient group, covering all rheumatology departments
in Latvia. Patients should be enrolled based on the same in-
clusion criteria and with similar phenotypic data as used in
the present study.
In conclusion, heterozygous states CA and GT at positions
-607 and -656, respectively, of IL-18 gene may influence
susceptibility to RA. More studies on a larger patient group
is needed, to explore this association in Latvian population.
On the basis of the investigated IL-18 polymorphisms, fe-
male patients with RA seem to represent a separate disease
subgroup.
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INTERLEIKÎNA 18 GÇNA PROMOTERA POLIMORFISMI LATVIJAS SLIMNIEKIEM AR REIMATOÎDO ARTRÎTU
Interleikîns 18 (IL-18) ir proinflamatorais citokîns, kas iesaistîts reimatoîdâ artrîta (RA) patoìençzç. Dati par to, vai ðî interleikîna
promotera polimorfismi var bût neatkarîgi RA ìençtiskie maríieri, ir pretrunîgi. Ðî pçtîjuma mçríis bija noteikt, vai IL-18 gçna promotera
polimorfismi -607 (rs 1946519) un -656 (rs 1946518) pozîcijâ ir saistîti ar RA un tâ îpatnîbâm Latvijas populâcijâ. Mçs izmeklçjâm 105
pacientus ar diagnosticçtu RA saskaòâ ar Amerikas reimatoloìijas koledþas diagnostiskajiem kritçrijiem. Veselo kontroïu DNS un
fenotipiskie dati iegûti no (Latvijas) Valsts iedzîvotâju genoma datu bâzes. Genotipi noteikti ar tieðu sekvençðanu. Polimorfismi pçtîti un
alçïu un genotipu bieþumi salîdzinâti starp RA slimniekiem un kontrolgrupu. P vçrtîba mazâka par 0,05 pieòemta par statistiski bûtisku.
Mûsu pçtîjumâ neatradâm bûtiskas atðíirîbas starp alçïu un genotipu bieþumu starp RA slimniekiem un kontrolgrupu. Tendence uz
asociâciju konstatçta starp IL-18-607C/A un -656G/T genotipiem sievietçm un kontrolgrupu (P = 0,084 un 0,097). Heterozigotiskus
genotipus -607CA un -656GT novçroja bieþâk RA grupâ, nekâ kontrolgrupâ (P = 0,046, P = 0,060). Atðíirîbas novçroja, salîdzinot
heterozigotisku genotipu -607CA un -656GT arî sievietçm (P = 0,041, P = 0,054). Secinâjumi: heterozigotiskie genotipi -607CA un
-656GT IL18 gçna promoterâ var ietekmçt RA uzòçmîbu. Pamatojoties uz izmeklçtiem IL18 polimorfismiem, RA slimnieces, ðíiet, pârstâv
atseviðíu slimîbas apakðgrupu.
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